cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.25934/pr00012063
title: Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as Add on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes

description: This trial is conducted in Africa, North and South America, Asia and Europe. The purpose of the trial is to compare the effect of once-weekly dosing of two dose levels of semaglutide versus insulin glargine once-daily on glycaemic control after 30 weeks of treatment in insulin-naïve subjects with type 2 diabetes.
DOI: 10.3535/bxl-tgb-wyt
title: Parastichtis suspecta Hübner, 1809

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.25934/pr00012064
title: Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes

description: This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of semaglutide once weekly versus placebo as add-on to basal insulin alone or basal insulin in combination with metformin in subjects with type 2 diabetes.
DOI: 10.3535/7ae-fbb-kys
title: Pyrausta cingulata Linnaeus, 1758

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/hex-6cx-pvt
title: Hypena rostralis (Linnaeus, 1758)

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.25934/pr00012065
title: Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes Who Are Insufficiently Controlled on Diet/Exercise Therapy or OAD Monotherapy

description: This trial is conducted in Asia. The aim of the trial is to investigate safety and efficacy of semaglutide once weekly in monotherapy or in combination with one OAD (oral anti-diabetic drug) in Japanese subjects with type 2 diabetes who are insufficiently controlled on diet/exercise therapy or OAD monotherapy.All subjects will continue their pre-trial treatment (diet and exercise therapy or OAD monotherapy in addition to diet and exercise therapy) during the trial.
DOI: 10.25934/pr00012066
title: Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily, Both as Monotherapy in Japanese Subjects With Type 2 Diabetes

description: This trial is conducted in Japan. The purpose is to compare the safety of once-weekly dosing of semaglutide (0.5 and 1.0 mg) versus sitagliptin (100 mg) once daily, both as monotherapy during 30 weeks of treatment in Japanese subjects with type 2 diabetes.
DOI: 10.3535/j6p-9gz-mym
title: Semioscopis steinkellneriana ([Denis & Schiffermüller], 1775)

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.25934/pr00012067
title: Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes. A 30-week Randomised, Double-blind, Double-dummy, Active-controlled, Parallel-group, Multi-centre and Multi-national Trial

description: This trial is conducted in Africa, Asia, Europe and South America. The aim of the trial is to compare the effect of once-weekly dosing of two dose levels of semaglutide versus sitagliptin 100 mg once-daily on glycaemic control after 30 weeks of treatment. Subjects will remain on their stable pre-trial metformin.
DOI: 10.3535/1wq-faj-has
title: Coranarta cordigera Thunberg, 1788

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/pn3-qgm-g8n
title: Agrotis exclamationis (Linnaeus, 1758)

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.25934/pr00012068
title: Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes

description: This trial is conducted globally. The aim of this trial is to investigate dose-finding of semaglutide administered subcutaneously once daily versus placebo and liraglutide in subjects with type 2 diabetes
DOI: 10.3535/n5r-8tr-wp9
title: Coranarta cordigera Thunberg, 1788

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.5281/zenodo.14989539
title: BETA-FOR_SP6_Gastropoda_2022/2023

description: This dataset includes records of gastropod species collected using pitfall traps across the 234 BETA-FOR patches. Two traps were installed 7 meters from the center of each patch, positioned in the northwest and southeast. Traps were emptied at the end of May, June, and July.

This dataset also includes records of gastropod species collected in leaf-litter samples. Five leaf-litter samples were collected 20 x 20 cm and 2 cm of the soil below. One sample was taken in the center of the patch, the other four in each cardinal direction 10 – 15 meters away from the center.

This dataset also includes records of gastropod species collected on and below deadwood. Two pieces of deadwood were chosen in each patch with at least 1 meter in length and a diameter of 10 cm. We tried to sample similar deadwood pieces in each patch. All gastropods on the deadwood and on the ground below were collected.

Sampling of the pitfall-traps was conducted in 2022 for 90 patches in the University Forest and 90 patches in the Bavarian Forest. In 2023, 18 patches in Hunsrück, Saarland, and Lübeck each, leading to a total of 54 patches. Sampling of the leaf-litter and deadwood was conducted in 2023 in all 234 patches.

All collected samples were sorted by the University of Würzburg and the University of Bayreuth and identified by Lisa Albert.
description: Variables Description################

*Region: the regions the patches are located in

*Patch_Nr: number of each patch

*patchLabelBETAFOR: unique BETA-FOR patch label

*Sampling_method: The way the sample was taken

*Trap_Nr: The number of each pitfall-trap

*dwc:Year: the year the sample was taken

*dwc:Month: the month the sample was taken

*Trap_ID: unique ID of each trap

*dwc:Scientific_name: name of the species in binary nomenklature. Arion_rufus includes Arion_vulgaris and Arion_circumscriptus includes all white-soled Arionidae since these species could not be separated in the pitfall-trap samples due to the loss of color.

*Abundance: Number of individuals which could be identified to species level for each species and each Trap_ID

*dwc:Identified_by: Name of the person who identified the species
DOI: 10.5281/zenodo.14989540
title: BETA-FOR_SP6_Gastropoda_2022/2023

description: This dataset includes records of gastropod species collected using pitfall traps across the 234 BETA-FOR patches. Two traps were installed 7 meters from the center of each patch, positioned in the northwest and southeast. Traps were emptied at the end of May, June, and July.

This dataset also includes records of gastropod species collected in leaf-litter samples. Five leaf-litter samples were collected 20 x 20 cm and 2 cm of the soil below. One sample was taken in the center of the patch, the other four in each cardinal direction 10 – 15 meters away from the center.

This dataset also includes records of gastropod species collected on and below deadwood. Two pieces of deadwood were chosen in each patch with at least 1 meter in length and a diameter of 10 cm. We tried to sample similar deadwood pieces in each patch. All gastropods on the deadwood and on the ground below were collected.

Sampling of the pitfall-traps was conducted in 2022 for 90 patches in the University Forest and 90 patches in the Bavarian Forest. In 2023, 18 patches in Hunsrück, Saarland, and Lübeck each, leading to a total of 54 patches. Sampling of the leaf-litter and deadwood was conducted in 2023 in all 234 patches.

All collected samples were sorted by the University of Würzburg and the University of Bayreuth and identified by Lisa Albert.
description: Variables Description################

*Region: the regions the patches are located in

*Patch_Nr: number of each patch

*patchLabelBETAFOR: unique BETA-FOR patch label

*Sampling_method: The way the sample was taken

*Trap_Nr: The number of each pitfall-trap

*dwc:Year: the year the sample was taken

*dwc:Month: the month the sample was taken

*Trap_ID: unique ID of each trap

*dwc:Scientific_name: name of the species in binary nomenklature. Arion_rufus includes Arion_vulgaris and Arion_circumscriptus includes all white-soled Arionidae since these species could not be separated in the pitfall-trap samples due to the loss of color.

*Abundance: Number of individuals which could be identified to species level for each species and each Trap_ID

*dwc:Identified_by: Name of the person who identified the species
DOI: 10.25934/pr00012069
title: Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes

description: This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes.
DOI: 10.3535/6pg-bvw-mhb
title: Laspeyria flexula [Denis & Schiffermüller], 1775

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/7t3-mvr-mkf
title: Agrotis exclamationis (Linnaeus, 1758)

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.25934/pr00012070
title: Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus. A 30-week Randomised, Double-blind, Placebo-controlled Trial

description: This trial is conducted in Asia, Europe and North America. The aim of the trial is to compare the effect of semaglutide s.c. 1.0 mg once-weekly versus placebo as add-on to sodium glucose co-transporter-2 inhibitor (SGLT-2i) monotherapy or in combination with either metformin or sulfonylurea on glycaemic control after 30 weeks of treatment in subjects with type 2 diabetes. Subjects will remain on their pre-trial medication.
DOI: 10.3535/00f-809-h6p
title: Agrotis exclamationis (Linnaeus, 1758)

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/xd0-ba0-hml
title: Agrotis exclamationis (Linnaeus, 1758)

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.25934/pr00012071
title: Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes

description: This trial is conducted in Africa, Asia, Europe, North and South America. The aim of the trial is to compare the effect of once-weekly (OW) dosing of subcutaneous semaglutide (1.0 mg) versus once-daily dosing of oral canagliflozin (300 mg) on glycaemic control in subjects with type 2 diabetes (T2D) on a background treatment of metformin
DOI: 10.3535/drl-tff-xtn
title: Mesapamea secalis (Linnaeus, 1758)

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/x19-y3g-c87
title: Mesapamea secalis (Linnaeus, 1758)

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.25934/pr00012072
title: Effect of Semaglutide Versus Placebo on the Progression of Renal Impairment in Subjects With Type 2 Diabetes and Chronic Kidney Disease

description: The researchers are doing this study to see if semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 diabetes. Participants will get semaglutide (active medicine) or placebo ('dummy medicine'). This is known as participants' study medicine - which treatment participants get is decided by chance. Semaglutide is a medicine, doctors can prescribe in some countries for the treatment of type 2 diabetes. Participants will get the study medicine in a pen. Participants will use the pen to inject the medicine in a skin fold once a week. The study will close when there is enough information collected to show clear result of the study. The total time participants will be in this study is about 3 to 5 years, but it could be longer.
DOI: 10.3535/25e-8kw-ybd
title: Gesneria centuriella [Denis & Schiffermüller], 1775

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/sz9-bzj-xf4
title: Xestia (Pachnobia) alpicola Zetterstedt, 1840

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.25934/pr00012073
title: Efficacy and Safety of Semaglutide 1.0 mg Once-weekly Versus Liraglutide 1.2 mg Once-daily as add-on to 1-3 Oral Anti-diabetic Drugs (OADs) in Subjects With Type 2 Diabetes

description: This study is conducted in Europe. The aim of the study is to compare the effect of semaglutide subcutaneous (s.c., under the skin) 1.0 mg once-weekly to liraglutide s.c.1.2 mg once-daily on blood sugar levels after 30 weeks of treatment in people with type 2 diabetes. The study will last approximately 9 months (37 weeks). Each participant will have 7 visits at the clinic and 3 phone calls with the study doctor. At the visits, participants will have a number of tests, for example: general health checks, blood samples, heart and eye checks etc. Participants will also fill in some forms about their health and satisfaction with their diabetes treatment.
DOI: 10.3535/7g5-l04-x9b
title: Xestia (Pachnobia) alpicola Zetterstedt, 1840

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.25934/pr00012074
title: Effect of Semaglutide Once-weekly Versus Insulin Aspart Three Times Daily, Both as Add on to Metformin and Optimised Insulin Glargine (U100) in Subjects With Type 2 Diabetes A 52-week, Multi-centre, Multinational, Open-label, Active-controlled, Two Armed, Parallel-group, Randomised Trial in Subjects With Type 2 Diabetes

description: This study will compare the effect of semaglutide once weekly to insulin aspart 3 times daily as add on to metformin and insulin glargine in people with type 2 diabetes. Participants will either get insulin glargine and semaglutide or insulin glargine and insulin aspart - which treatment the participant get is decided by chance. Insulin glargine is taken once a day and semaglutide once a week. Insulin aspart is taken three times per day before a meal. All three medicines come in pre-filled pens for injection under the skin. The study will last for about 71 weeks. If participant's blood sugar gets under or over certain values participant will only participate in 14 weeks. The study doctor will inform the participant about this. The participant will have 15 clinic visits and 22 phone calls with the study doctor.
DOI: 10.25934/pr00012075
title: Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Clinical Trial

description: The main purpose of this study is to compare the effects of semaglutide (Ozempic®) with the effects of other treatments for type 2 diabetes in a normal practice setting. The participant will be assigned by chance (like flipping a coin) to one of the following treatment groups: Group 1: semaglutide (Ozempic®) (by injection into skin) Group 2: standard of care antidiabetic medication (oral or injectable). The participant has an equal chance of being in either of the treatment groups. Neither the participant nor the study doctor or study staff will be able to pick which group the participant is in, but the participant will know which study drug the participant has been assigned to. The study doctor will provide the participant with a prescription for the study diabetes medication based on the treatment group the participant is assigned. The participation will last about 2 years.
DOI: 10.3535/4kc-qvb-lex
title: Xestia (Megasema) c-nigrum (Linnaeus, 1758)

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.25934/pr00012076
title: Efficacy and Safety of Semaglutide 2.0 mg s.c. Once-weekly Compared to Semaglutide 1.0 mg s.c. Once-weekly in Subjects With Type 2 Diabetes

description: This study compares the effect of two doses of semaglutide (1.0 mg and 2.0 mg) in people with type 2 diabetes (T2D). People taking part in the study will take the medicine together with their current diabetes medicine (sulphonylurea and/or metformin). Participants will get a dose of either 1.0 mg or 2.0 mg semaglutide once a week - which dose is decided by chance. Participants will inject semaglutide under the skin once a week. The study will last for about 49 weeks. Participants will have 9 clinic visits and 2 phone calls with the study doctor. At the visits participants will have blood taken and eye tests done. Women cannot take part if pregnant, breast-feeding or planning to become pregnant during the study period. Female participants who can get pregnant will be checked 11 times for pregnancy via urine tests.
DOI: 10.3535/j1t-1n9-phc
title: Gynaephora (Gynaephora) selenitica (Esper, 1789)

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/lrx-lw9-64j
title: Melitaea cinxia Linnaeus, 1758

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.25934/pr00012077
title: Effects of Semaglutide on Functional Capacity in Patients With Type 2 Diabetes and Peripheral Arterial Disease

description: This study is done to see if semaglutide has an effect on walking ability compared with placebo (dummy medicine) in people with peripheral arterial disease (PAD) and type 2 diabetes. Participants will either get semaglutide or placebo ("dummy") medicine - which treatment participants get is decided by chance. Semaglutide is a medicine for type 2 diabetes that can be prescribed by doctors in some countries. Participants will get the study medicine (semaglutide or placebo) in a pre-filled pen for injection. Participants must inject it once a week into the stomach area, thigh, or upper arm, at any time of the day. The study will last for about 59 weeks. Participants will have 8 clinic visits and 1 phone call with the study doctor. At some clinic visits, participants will have blood tests. At some visits participants will also do a treadmill test to measure how far they can walk. Women cannot take part if pregnant, breast-feeding or planning to become pregnant during the study period.
DOI: 10.3535/a77-zpr-mvt
title: Gesneria centuriella [Denis & Schiffermüller], 1775

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/gkh-4mc-vtx
title: Melitaea cinxia Linnaeus, 1758

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.25934/pr00012078
title: A Trial to Complare the Injection Site Pain Experience of Semaglutide 0.25 mg and Dulaglutide 0.75 mg Administered sc

description: This study in healthy men and women looks at the injection site experience of semaglutide and dulaglutide given subcutaneously (s.c., under the skin). Participants will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day. The 2 injections will be given at least 30 minutes apart, one in each side of the stomach. Participants will be in the clinic research center for 1 day. A follow-up phone call will take place between 4 and 5 weeks after the injections were given.
DOI: 10.3535/qr5-rb7-3c5
title: Agrochola (Anchoscelis) Guenée, 1839

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/s2r-100-3b6
title: Noctua pronuba Linnaeus, 1758

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.25934/pr00012079
title: Investigation of Clinical Comparability of Semaglutide Drug Products Based on the Proposed and the Approved Drug Substance Manufacturing Processes in Participants With Type 2 Diabetes

description: The study compares two semaglutide medicines and looks at how well they control blood sugar levels, in participants with type 2 diabetes (T2D). Participants will either get the currently available semaglutide or the semaglutide which is produced through a new manufacturing process. Participants need to take one injection of semaglutide once a week, on the same day of every week. Participants will have a total of 11 clinic visits and the study will last for about 35 weeks (approximately 8 months).
DOI: 10.25934/pr00012080
title: Safety and Tolerability of Weekly Semaglutide 0.5 mg or 1.0 mg in Chilean Subjects With Type 2 Diabetes

description: This study is testing the safety and tolerability of subcutaneous semaglutide in participants with type 2 diabetes (T2D) in Chile. Participants will get a once-weekly subcutaneous injection of semaglutide in doses decided by the study doctor's criteria, according to participant's personal needs. The study will last for about 24 weeks. Participants will have 4 clinic visits and 2 phone calls. Participants will have 3 laboratory tests during the study (blood and urine samples).
DOI: 10.3535/vgp-qkh-bkt
title: Cerastis leucographa [Denis & Schiffermüller], 1775

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.25934/pr00012081
title: Investigation of Once-weekly Semaglutide S.C. Dose-Response in Patients With Type 2 Diabetes and Overweight - a Participant- and Investigator-blinded and Sponsor Open-label Study

description: This study compares how three doses of semaglutide work in participants with type 2 diabetes (T2D) and overweight who are taking metformin. The study will look mainly at how well participant's blood sugar and participant's body weight are controlled when they are taking the study medicine at different doses. Participants will either get semaglutide \[2 milligrams (mg), 8 mg, or 16 mg\] or semaglutide placebo (a dummy medicine). Participants will take the study medicine with an injection pen called NovoPen®4. The injection pen is a medical tool with a needle used to inject the study medicine under the skin. The study will last for about 52 weeks. Participants will have 13 clinic visits and 4 phone calls.
DOI: 10.3535/7q4-jaz-llw
title: Xestia (Megasema) c-nigrum (Linnaeus, 1758)

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.3535/pzv-k70-ne9
title: Trachea atriplicis (Linnaeus, 1758)

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.
DOI: 10.25934/pr00012082
title: Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus

description: This trial is conducted globally. The aim of this trial is to investigate safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus.
DOI: 10.3535/tnq-76a-ckq
title: Mesapamea secalis (Linnaeus, 1758)

description: Digital Specimen for the physical specimen hosted at Finnish Museum of Natural History.